Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.57 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.56 |
| ▸ | CXCR1 | P25024 | 12/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2403463 | 0.90 | CYP1A2 (0.69) | CYP1A2CYP19A1CYP2C9CYP2C19SMPD1 | |
| SCHEMBL17951705 | 0.85 | CYP1A2 (0.67) | CYP1A2CYP19A1CYP2C9CYP2C19SMPD1 | |
| SCHEMBL19600983 | 0.85 | CXCR1 (0.73) | CYP1A2CYP19A1CYP2C9CYP2C19SMPD1 | |
| SCHEMBL7339631 | 0.85 | CYP1A2 (0.63) | CYP1A2CYP19A1CYP2C9CYP2C19SMPD1 | |
| SCHEMBL6538529 | 0.84 | CYP1A2 (0.59) | CYP1A2CYP19A1CYP2C9CYP2C19SMPD1 | |
| SCHEMBL10929143 | 0.83 | CXCR1 (0.66) | CYP1A2CYP19A1CYP2C9CYP2C19SMPD1 | |
| SCHEMBL17822356 | 0.83 | CYP1A2 (0.60) | CYP1A2CYP19A1CYP2C9CYP2C19SMPD1 | |
| SCHEMBL903875 | 0.82 | SMPD1 (0.61) | CYP1A2CYP19A1CYP2C9CYP2C19SMPD1 | |
| SCHEMBL2353533 | 0.82 | RARB (0.64) | CYP1A2CYP19A1CYP2C9CYP2C19SMPD1 | |
| SCHEMBL7403884 | 0.82 | RARB (0.64) | CYP1A2CYP19A1CYP2C9CYP2C19SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743776-B2 | ANTIFUNGAL, BETA-1,3-GLUCAN SYNTHASE INHIBITOR, PNEUMOCYSTIS CARINII; AMIDATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-01 | — | — | US | claimed |
| US-20020193560-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2002-12-19 | — | — | US | claimed |
| EP-0941236-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-15 | — | — | EP | claimed |
| WO-1998023637-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-04 | — | — | WO | claimed |
| WO-2016201283-A1 | ANTIFUNGAL AGENTS | CIDARA THERAPEUTICS, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| EP-2763971-B1 | PREPARATION OF MICAFUNGIN INTERMEDIATES | SANDOZ AG (CH) | 2016-06-08 | — | — | EP | disclosed |
| US-7285619-B2 | Echinocandin derivatives, their method of preparation and their application as anti-fungal agents | AVENTIS PHARMA S.A. (FR) | 2007-10-23 | — | — | US | disclosed |
| US-7192920-B2 | Derivatives of echinocandine, their preparation process and their use as antifungals | AVENTIS PHARMA SA (FR) | 2007-03-20 | — | — | US | disclosed |
| US-7160983-B2 | Echinocandin derivatives, their method of preparation and their application as anti-fungal agents | AVENTIS PHARMA S.A. (FR) | 2007-01-09 | — | — | US | disclosed |
| US-6743776-B2 | ANTIFUNGAL, BETA-1,3-GLUCAN SYNTHASE INHIBITOR, PNEUMOCYSTIS CARINII; AMIDATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-01 | — | — | US | disclosed |
| US-20020193560-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2002-12-19 | — | — | US | disclosed |
| EP-0941236-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998023637-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193560-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | NGLY1, CHIT1, MANBA | CYP1A2 3431/4885CYP19A1 4180/4885CYP2C9 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.